Exchange: NASDAQ·Updated 07:31 PM EST

SNDX News

News
all
press releases
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Gets Price Target Cut from UBS Group
UBS Group dropped their target price on Syndax Pharmaceuticals from $33.00 to $31.00 and set a "buy" rating on the stock in a report on Friday...
MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Gets Price Target Cut from UBS Group
UBS Group dropped their target price on Syndax Pharmaceuticals from $33.00 to $31.00 and set a "buy" rating on the stock in a report on Friday...
MarketBeat
More News
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week Low - What's Next...
MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPR NewswireNEW YORK, Nov. 5, 2026 NEW YORK, Nov. 5, 2026...
PR Newswire
Syndax (SNDX) delivered earnings and revenue surprises of -5.77% and +2.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026...
PR Newswire
Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. (Syndax or the Company) (NASDAQ: SNDX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
Zacks
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)PR NewswireNEW YORK, Oct. 13, 2026SNDX shareholders saw the market open to losses of more than...
PR Newswire

Advertisement|Remove ads.